UCL Discovery - Browse by UCL Departments and Centres

Detailed search
Browse by:

Department | Year | Latest

For everyone

About UCL Discovery
Open Access
Using UCL Discovery:
- Finding research
- Using research
Statistics:
- Top 20 most downloaded
- Other statistics
FAQ

For UCL authors

Any questions?

Bookmark & Share

Browse by UCL Departments and Centres

Up a level

Group by: Author | Type

Jump to: A | B | C | D | F | G | H | J | L | M | N | O | P | R | S | T | V | W

Number of items: 172.

A

Anderson, FM and O'Hare, CC and Hartley, JA and Robins, DJ (2000) Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agents. ANTI-CANCER DRUG DES , 15 (2) 119 - 126.

Arkenau, H-T and Hegglin, I and Luthi, U and Gebbers, J-O (2000) Trichosporosis | Trichosporonose. Schweizerische Medizinische Wochenschrift , 130 (49) 1914 - 1914.

Arkenau, H-T and Lüthi, U (2000) Soap-bubble lesions | Seifenblasenläsionen. Schweizerische Medizinische Wochenschrift , 130 (51-52) 2017 - 2017.
An open access publication

Arkenau, H-T and Luthi, U and Gebbers, J-O (2000) Amyloidomas | Amyloidome. Schweizerische Medizinische Wochenschrift , 130 (35) 1244 - 1244.

Arkenau, HT and Hegglin, I and Lüthi, U (2000) [Trichosporosis]. Schweiz Med Wochenschr , 130 (49) 1914 - ?.

Arkenau, HT and Lüthi, U (2000) [Amyloidoma]. Schweiz Med Wochenschr , 130 (35) 1244 - ?.

Arris, CE and Boyle, FT and Calvert, AH and Curtin, NJ and Endicott, JA and Garman, EF and Gibson, AE and Golding, BT and Grant, S and Griffin, RJ and Jewsbury, P and Johnson, LN and Lawrie, AM and Newell, DR and Noble, MEM and Sausville, EA and Schultz, R and Yu, W (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J MED CHEM , 43 (15) 2797 - 2804.

Azzabi, AS and Calvert, AH and Verrill, M and Kelly, C and Lind, MJ and Newell, DR and Griffin, MJ and Fishwick, K and Chapman, F and Simmonds, D and Proctor, M and Pilkington, M and Boddy, AV (2000) Phase I and pharmacokinetic study of temozolomide and paclitaxel in the treatment of malignant melanoma. Clinical Cancer Research , 6 539 - ?.

B

Baddeley, H and Brodrik, PM and Taylor, NJ and Abdelatti, MO and Jordan, LC and Vasudevan, AS and Phillips, H and Saunders, MI and Hoskin, PJ (2000) Gas exchange parameters in radiotherapy patients during breathing of 2%, 3.5% and 5% carbogen gas mixtures. British Journal of Radiology , 73 (874) 1100 - 1104.

Barlow, HC and Bowman, KJ and Curtin, NJ and Calvert, AH and Golding, BT and Huang, B and Loughlin, PJ and Newell, DR and Smith, PG and Griffin, RJ (2000) Resistance-modifying agents. Part 7: 2, 6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha(1)-acid glycoprotein (AGP). BIOORG MED CHEM LETT , 10 (6) 585 - 589.

Bentley, J and Arris, CE and Boyle, FT and Calvert, AH and Curtin, NJ and Endicott, JA and Gibson, AE and Golding, BT and Grant, S and Griffin, RJ and Jewsbury, PJ and Johnson, LN and Noble, MEM and Newell, DR (2000) Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors. Clinical Cancer Research , 6 328 - ?.

Bentzen, SM and Hoskin, P and Roos, D and Nielsen, OS (2000) Fractionated radiotherapy for metastatic bone pain: Evidence- based medicine or ...? International Journal of Radiation Oncology Biology Physics , 46 (3) 681 - 682.

Bentzen, SM and Saunders, MI and Dische, S and Parmar, MK (2000) Updated data for chart in NSCLC: Further analyses. Radiotherapy And Oncology , 55 (1) 86 - 87.

Berardi, R and Strauss, S and Blake, D and Whelan, JS (2000) Is it safe to substitute oral for intravenous mesna? A case control study. In: ASCO, New Orleans May 2000 Proc ASCO 2000;19: 609.

Beverley, PCL and Maini, MK (2000) Differences in the regulation of CD4 and CD8 T-cell clones during immune responses. In: PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES. (pp. 401 - 406). ROYAL SOC LONDON

Bhatia, J and Sharma, SK and Chester, KA and Pedley, RB and Boden, RW and Read, DA and Boxer, GM and Michael, NP and Begent, RH (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer , 85 (4) 571 - 577.

Bhatia, J and Sharma, SK and Chester, KA and Pedley, RB and Boden, RW and Read, DA and Boxer, GM and Michael, NP and Begent, RHJ (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv :: carboxypeptidase G2 fusion protein. INT J CANCER , 85 (4) 571 - 577.

Bhatia, J and Sharma, SK and Pedley, BR and Boxer, G and Robson, L and Begent, RHJ and Chester, K (2000) In vitro and in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: British Journal of Cancer. (pp. 170 - 170).

Bhatia, J and Sharma, SK and Pedley, BR and Boxer, G and Robson, L and Begent, RHJ and Chester, KA (2000) In vitro & in vivo stability of purified MFE 23 :: CPG2 fusion protein from Pichia pastoris. In: British Journal of Cancer. (pp. 71 - 71).

Boddy, AV and Griffin, MJ and Wright, JG and Sludden, JA and Thomas, HD and Fishwick, K and Plummer, R and Highley, M and Calvert, AH (2000) Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer. British Journal of Cancer , 83 203 - ?.

Boehm, MK and Corper, AL and Wan, T and Sohi, MK and Sutton, BJ and Thornton, JD and Keep, PA and Chester, KA and Begent, RH and Perkins, SJ (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. Biochem J , 346 Pt 2 519 - 528.

Boehm, MK and Corper, AL and Wan, T and Sohi, MK and Sutton, BJ and Thornton, JD and Keep, PA and Chester, KA and Begent, RHJ and Perkins, SJ (2000) Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts. BIOCHEM J , 346 519 - 528.

Brooks, N and McHugh, PJ and Lee, M and Hartley, JA (2000) Alteration in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove. CHEM BIOL , 7 (9) 659 - 668.

Burcombe, RJ and Makris, A and Richman, PI and Daley, F and Noble, S and Wilson, GD (2000) Persistence of c-erbB-2 overexpression after neoadjuvant chemotherapy for primary breast cancer. British Journal of Cancer , 83 36 - ?.

Burcombe, RJ and Ostler, PJ and Ayoub, AW and Hoskin, PJ (2000) The role of staging CT scans in the treatment of prostate cancer: A retrospective audit. Clinical Oncology , 12 (1) 32 - 35.

C

Calabrese, CR and Curtin, NJ and Canan-Koch, SS and Batey, MA and Thomas, HD and Kyle, S and Wang, LZ and Boritzki, TJ and Webber, SE and Griffin, RJ and Golding, BT and Hostomsky, Z and Calvert, AH and Newell, DR (2000) Design and evaluation of novel potent inhibitors of poly(ADP-ribose) polymerase. Clinical Cancer Research , 6 150 - ?.

Calvert, H and Sessa, C and Carmichael, J and Calvert, P and Zucchetti, M and Marsoni, S and Van den Bosch, S and Robinson, A and Verdi, E and Camboni, G (2000) An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex. ANN ONCOL , 11 132 - 132.

Calvert, P and Jayson, G and Atkinson, R and Ganesan, T and Cervantes-Ruiperez, A and Vasey, P and Adams, M and Boven, E and Calvert, AH and Cheverton, P (2000) Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane. Annals of Oncology , 11 372P - ?.

Calvert, PM and O'Neill, V and Azzabi, A and Hughes, A and Plummer, R and Twelves, C and Robinson, A and Machan, MA and Dimitrijevic, S and Moss, D and Rothermel, J and Cohen, P and Chen, T and Man, A and Calvert, AH (2000) A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours. Clinical Cancer Research , 6 575 - ?.

Casey, JL and Pedley, RB and King, DJ and Boden, R and Chapman, A and Yarranton, GTAB and R, HJ (2000) Improved tumour targetting of divalent Fab’ fragments modified with polyethylene glycol. Tumor Targeting , 4 235 - 244.

Casey, JL and Pedley, RB and King, DJ and Boden, R and Chapman, AP and Yarranton, GT and Begent, RHJ (2000) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. Tumor Targeting , 4 (4) 235 - 244.

Cerone, MA and Marchetti, A and Bossi, G and Blandino, G and Sacchi, A and Soddu, S (2000) p53 is involved in the differentiation but not in the differentiation-associated apoptosis of myoblasts. Cell Death Differ , 7 (5) 506 - 508. 10.1038/sj.cdd.4400676.

Chang, J and Powles, TJ and Allred, DC and Ashley, SE and Makris, A and Gregory, RK and Osborne, CK and Dowsett, M (2000) Prediction of clinical outcome from primary tamosifen by expression of biologic markers in breast cancer patients. Clinical Cancer Research , 6 (2) 616 - 621.

Chester, KA and Bhatia, J and Boxer, G and Cooke, SP and Flynn, AA and Huhalov, A and Mayer, A and Pedley, RB and Robson, L and Sharma, SK and Spencer, DIR and Begent, RHJ (2000) Clinical applications of phage-derived sFvs and sFv fusion proteins. DISEASE MARKERS , 16 (1-2) 53 - 62.

Chester, KA and Mayer, A and Bhatia, J and Robson, L and Spencer, DI and Cooke, SP and Flynn, AA and Sharma, SK and Boxer, G and Pedley, RB and Begent, RH (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. Cancer Chemother Pharmacol , 46 Suppl S8 - 12.

Chester, KA and Mayer, A and Bhatia, J and Robson, L and Spencer, DIR and Cooke, SP and Flynn, AA and Sharma, SK and Boxer, G and Pedley, RB and Begent, RHJ (2000) Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer. In: CANCER CHEMOTHERAPY AND PHARMACOLOGY. (pp. S8 - S12). SPRINGER-VERLAG

Clingen, PH and Denholm, EE and De Silva, IU and Hockey, A and Hartley, JA (2000) Response of human DNA repair defective cell lines to DNA interstrand agents. British Journal of Cancer , 83 138 - ?.

Clingen, PH and Denholm, EE and De Silva, IU and Hockey, A and Hartley, JA and CRC Drug DNA Interaction Res Grp, (2000) Response of human DNA repair defective cell lines to DNA interstrand agents. BRIT J CANCER , 83 63 - 63.

Cooke, SP and Boxer, GM and Spencer, DIR and Lawrence, L and Pedley, RB and Chester, KA and Begent, RHJ (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. British Journal of Cancer , 83 14 - ?.

Cooooke, SP and Boxer, GM and Spencer, DIR and Lawrence, L and Pedley, RB and Chester, KA and Begent, RHJ (2000) Tumour vascular targeting using a novel anti-vascular endothelial cell growth factor (VEGF) scFv antibody. In: (Proceedings) British Journal of Cancer. (pp. 14 - 14).

Cunningham, D and Mainwaring, PN and Gregory, W and Hoskin, P and Hancock, B and Smith, P and Hudson, GV and Linch, D (2000) Mitoxantrone is superior to doxorubicin in a multi-agent weekly regimen for patients with high-grade lymphoma over the age of 60 years: Results of a BNLI randomised trial of PACEBO vs. British Journal of Cancer , 83 (Su 1 - ?.

Curtin, NJ and Calvert, AH and Canan-Koch, S and Durkacz, BW and Griffin, RJ and Golding, BT and Hostomsky, Z and Kyle, S and Li, J and Maegley, K and Newell, DR and Wang, LZ and Webber, SE and White, A and Yu, XH (2000) Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines. Clinical Cancer Research , 6 205 - ?.

D

De Silva, IU and McHugh, PJ and Clingen, PH and Hartley, JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. MOL CELL BIOL , 20 (21) 7980 - 7990.

Dearling, JLJ and Flynn, AA and Pagoulatos, C and Wilson, GD and Woodcock, M and Denholm, E and Hartley, J and Begent, RHJ and Pedley, RB (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. British Journal of Cancer , 83 (Suppl) 173 - ?.

Dearling, JLJ and Flynn, AA and Pagoulatos, C and Wilson, GD and Woodcock, M and Denholm, E and Hartley, J and Begent, RHJ and Pedley, RB (2000) Influence of tumour cell response and nuclide selection on the efficacy of RIT. In: BRIT J CANCER. (pp. 72 - 72). CHURCHILL LIVINGSTONE

Dearling, JLJ and Flynn, AA and Watson, RJ and Boxer, GM and Sutcliffe-Goulden, J and Boden, R and Begent, RHJ and and Pedley, RB (2000) : Potential for use of [C-14]2DG as a predictor of [F-18]FDG tumour distribution for assessment of therapeutic efficacy. In: Nuclear Medicine Communications. (pp. 394 - 395).

Delaney, CA and Wang, LZ and Kyle, S and White, AW and Calvert, AH and Curtin, NJ and Durkacz, BW and Hostomsky, Z and Newell, DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. CLIN CANCER RES , 6 (7) 2860 - 2867.

Di Francesco, AM and Hargreaves, RHJ and Wallace, TW and Mayalarp, SP and Hazrati, A and Hartley, JA and Butler, J (2000) Anti-tumour properties of novel diaziridinylquinones. British Journal of Cancer , 83 152 - ?.

Di Francesco, AM and Hargreaves, RHJ and Wallace, TW and Mayalarp, SP and Hazratis, A and Hartley, JA and Butler, J (2000) The abnormal cytotoxicities of 2,5-diaziridinyl-1,4-benzoquinone-3-phenyl esters. ANTI-CANCER DRUG DES , 15 (5) 347 - 359.

Duchesne, GM and Bolger, JJ and Griffiths, GO and Roberts, JT and Graham, JD and Hoskin, PJ and Fossa, SD and Uscinska, BM and Parmar, MKB (2000) A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: Results of Medical Research Council Trial BA09. International Journal of Radiation Oncology Biology Physics , 47 (2) 379 - 388.

Dunlop, DJ and Connery, L and O, BM and Thatcher, N and Lee, SM and Hill, S and Thatcher, N (2000) Phase II study of carboplatin and vinorelbine in small cell lung cancer. In: (Proceedings) 2000 ASCO Annual Meeting/36th Annual Meeting, New Orleans, LA.. (pp. 518a - ?). Proceedings of the American Society of Clinical Oncology

Dunlop, DJ and O'Brien, M and Lee, S and Hill, S and Thatcher, N (2000) Multicentre phase II study of carboplatin (AUC 5) and vinorelbine in small cell lung cancer (SCLC). In: (Proceedings) British Cancer Research Meeting, Brighton.. (pp. 42 - ?). British Journal of Cancer

F

Flynn, AA and Green, AJ and Pedley, RB and Boxer, GM and Dearling, J and Watson, R and Boden, B and Begent, RHJ (2000) A model based approach for the optimisation of radioimmunotherapy through antibody design and radionuclide selection. Cancer Biotherapy and Radiopharmaceuticals , 15 (4 2000)

Flynn, AA and Pedley, RB and Green, AJ and Boxer, GM and Dearling, J and Watson, R and Boden, B and Begent, RHJ (2000) Multiparameter analysis using 3D reconstructions of digital images showing the spatial and temporal distribution of factors influencing radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals , 15 (4 2000)

Francis, RJ and Sharma, SK and Sena, L and Springer, C and Green, AJ and Hope-Stone, LD and Martin, J and Adamson, KL and O'Malley, D and Tsiompanou, E and Shahbakhti, H and Webley, S and Hochhauser, D and Hilson, AJ and Begent, RHJ (2000) A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. British Journal of Cancer , 83 (Suppl) 18 - ?.

Friedman, HS and Kerby, T and Calvert, H (2000) Temozolomide and treatment of malignant glioma. CLIN CANCER RES , 6 (7) 2585 - 2597.

G

Gibson, V and Anderson, RJ and Hartley, JA and McAdam, SR and Cairns, D (2000) Anthraquinone-oligodeoxynucleotide conjugates as inhibitors of gene transcription. J PHARM PHARMACOL , 52 (6) 599 - 602.

Gorodetsky, R and Lotan, C and Piggot, K and Pierce, L and Polyansky, I and Dische, S and Saunders, MI and Lichter, AS and Vexler, A (2000) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy (vol 45, pg 893, 1999). International Journal of Radiation Oncology Biology Physics , 47 (2) 545 - 545.

Griffin, RJ and Arris, CE and Bleasdale, C and Boyle, FT and Calvert, AH and Curtin, NJ and Dalby, C and Kanugula, S and Lembicz, NK and Newell, DR and Pegg, AE and Golding, BT (2000) Resistance-modifying agents. 8. Inhibition of O-6-alkylguanine-DNA alkyltransferase by O-6-alkenyl-, O-6-cycloalkenyl-, and O-6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O-6-(1-cyclopentenylmethyl)guanine. J MED CHEM , 43 (22) 4071 - 4083. 10.1021/jm000961o.

Griffin, RJ and Arris, CE and Calvert, AH and Curtin, NJ and Jewsbury, P and Endicott, JA and Gibson, AE and Boyle, FT and Golding, BT and Grant, S and Johnson, LN and Noble, MEM and Newell, DR and Lawrie, A (2000) Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors. Abstracts of Papers of the American Chemical Society , 219 296 - MEDI.

H

Hampel, C and Tolner, B and Webley, SD and Lam, E and Hartley, JA and Hochhauser, D (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. British Journal of Cancer , 83 (Suppl) 65 - ?.

Hampel, C and Tolner, B and Webley, SD and Lam, E and Hartley, JA and Hochhauser, D (2000) Role of E2F-1 in chemosensitivity to minor groove binding agents. BRIT J CANCER , 83 23 - 23.

Hargreaves, RHJ and Hartley, JA and Butler, J (2000) Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. FRONT BIOSCI , 5 E172 - E180.

Harland, PC and Harland, SJ (2000) John Charles Harland - Obituaries. BMJ (Clinical Research Ed.) , 320 (7242) 1149 - 1149.

Harland, SJ (2000) Conundrum of the hereditary component of testicular cancer. LANCET , 356 (9240) 1455 - 1456.

Hartley, JA and Brooles, PJ and Mc Hugh, PJ and Clingen, PH and Gregson, SJ and Howard, PW and and Thurston, DE (2000) SJG-136 (NSC-D694501)-A novel DNA sequence specific minor groove crosslinking agent with significant antitumor activity. PROC AM ASSOC CANCER RES , 41 2703 - ?.

Hartley, JA and Hazrati, A and Hodgkinson, TJ and Kelland, LR and Khanim, R and Shipman, M and Suzenet, F (2000) Synthesis, cytotoxicity and DNA cross-linking activity of symmetrical dimers based upon the epoxide domain of the azinomycins. CHEM COMMUN (23) 2325 - 2326.

Hartley, JA and Hazrati, A and Kelland, LR and Khanim, R and Shipman, M and Suzenet, F and Walker, LF (2000) A synthetic azinomycin analogue with demonstrated DNA cross-linking activity: Insights into the mechanism of action of this class of antitumor agent. ANGEW CHEM INT EDIT , 39 (19) 3467 - +.

Hartley, JA and Hazrati, A and Kelland, LR and Khanim, R and Shipman, M and Suzenet, F and Walker, LF (2000) A Synthetic Azinomycin Analogue with Demonstrated DNA Cross-Linking Activity: Insights into the Mechanism of Action of this Class of Antitumor Agent The authors gratefully acknowledge the financial support provided by the CRC and the EPSRC. We are indebted to the EPSRC National Mass Spectrometry Centre for performing mass spectral measurements, and the EPSRC Chemical Database Service at Daresbury.1. Angew Chem Int Ed Engl , 39 (19) 3467 - 3470.

Hochhauser, D (2000) Relevance of mitochondrial DNA in cancer. LANCET , 356 (9225) 181 - 182.

Horwich, A and Oliver, RTD and Wilkinson, PM and Mead, GM and Harland, SJ and Cullen, MH and Roberts, JT and Fossa, SD and Dearnaley, DP and Lallemand, E and Stenning, SP and MRC Testicular Tumour Working Par, (2000) A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. BRIT J CANCER , 83 (12) 1623 - 1629. 10.1054/bjoc.2000.1498.

Hoskin, PJ (2000) Palliative radiotherapy for disseminated disease. In: Greco, C and Zelefsky, MJ, (eds.) Radiotherapy of prostate cancer. (463 - 477). Harwood Academic Publishers: Amsterdam.

Hoskin, PJ (2000) Bone metastases - radiotherapy. In: Rubens, RD and Mundy, GR and Martin, D, (eds.) Cancer and the skeleton. (159 - 170). : London.

Hoskin, PJ and Phillips, H and Jackson, S and Wims, P and Verma, N and Saunders, MI (2000) Carbogen and nicotinamide with radical radiotherapy for bladder cancer: Updated Phase II results and launch of the BCON Phase III randomised trial. British Journal of Cancer , 83 84 - ?.

Hoskin, PJ and Stratford, MRL and Folkes, LK and Regan, J and Yarnold, JR (2000) Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. The Lancet , 355 (9213) 1428 - 1429.

Hoskin, PJ and Vidler, K (2000) Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. British Journal of Radiology , 73 (872) 864 - 866.

Hughes, AN and Griffin, MJ and Newell, DR and Calvert, AH and Johnston, A and Kerr, B and Lee, C and Liang, B and Boddy, AV (2000) Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq (TM)) and paclitaxel. BRIT J CANCER , 82 (9) 1519 - 1527.

J

Jankowska, PJ and Babb, P and Quinn, M and Whelan, JS (2000) A population based study of the incidence and mortality for osteosarcoma in England and Wales. In: British Cancer Research Meeting, Brighton July 2000 Br J Cancer 2000;83 suppl 1:17.

Joiner, M and Short, S and Mayes, C and Lambin, P and Marples, B and Shah, N and Saunders, MI (2000) Low dose hypersensitivity and induced radioresistance: Possibilities for therapy and implications for radioprotection. International Journal of Radiation Oncology Biology Physics , 46 (3) 692 - 692.

L

Leonard, P and Ledermann, J and James, R and Hochhauser, D and Seymour, M (2000) Phase II study of irinotecan and high dose infusional 5-fluorouracil (5-FU) and folinic acid for first and second line treatment of advanced colorectal cancer. ANN ONCOL , 11 44 - 45.

Leonard, P and Ledermann, JA and James, R and Hochhauser, D and Seymour, M (2000) Phase II study of irinotecan and high dose infusional 5-FU and folinic acid (modified de Gramont) for first-line treatment of advanced or metastatic colorectal cancer. British Journal of Cancer , 83 44 - ?.

Lo, SK and Tolner, B and Rogers, G and Schapira, AHV and Hartley, JA and Hochhauser, D (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. British Journal of Cancer , 83 56 - ?.

Lo, SK and Tolner, B and Rogers, G and Schapira, AHV and Hartley, JA and Hochhauser, D (2000) Assessment of mitochondrial DNA damage by chemotherapeutic agents. BRIT J CANCER , 83 22 - 22.

M

Maini, MK and Gudgeon, N and Wedderburn, LR and Rickinson, AB and Beverley, PCL (2000) Clonal expansions in acute EBV infection are detectable in the CD8 and not the CD4 subset and persist with a variable CD45 phenotype. J IMMUNOL , 165 (10) 5729 - 5737.

Mayer, A and Flynn, AA and Tsiompanou, E and Pedley, RB and Dearling, J and Boden, R and Begent, RHJ (2000) Radioimmunotherapy is more effective in small tumours due to higher dose and dose rate. In: BRIT J CANCER. (pp. 32 - 32). CHURCHILL LIVINGSTONE

Mayer, A and Tsiompanou, E and O'Malley, D and Boxer, GM and Bhatia, J and Flynn, AA and Chester, KA and Davidson, BR and Lewis, AAM and Winslet, MC and Dhillon, AP and Hilson, AJW and Begent, RHJ (2000) Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. CLIN CANCER RES , 6 (5) 1711 - 1719.

McHugh, PJ and Hartley, JA (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. British Journal of Cancer , 83 139 - ?.

McHugh, PJ and Hartley, JA and CRC Drug DNA Interactions Res Grp, (2000) Defining the pathways involved in the initiation and resolution steps of DNA interstrand crosslink repair. BRIT J CANCER , 83 63 - 63.

McHugh, PJ and Sones, WR and Hartley, JA (2000) Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. MOL CELL BIOL , 20 (10) 3425 - 3433.

McNeish, IA and Kanfer, EJ and Haynes, R and Agarwal, R and Harland, SJ and Newlands, ES and Seckl, MJ (2000) Paclitaxel-containing high dose chemotherapy for relapsed or refractory germ cell tumours. British Journal of Cancer , 83 86 - ?.

Meyer, T and Rustin, GJ (2000) Role of tumour markers in monitoring epithelial ovarian cancer. BRITISH JOURNAL OF CANCER , 82 (9) 1535 - 1538.

Middleton, MR and Lee, SM and Aranc, and A, and Wood, M and Thatcher, N and Margison, GP (2000) 06-methyguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. International Journal of Cancer , 88 (3) 469 - 473.

Middleton, MR and Lorigan, P and Owens, J and Ashcroft, L and Lee, SM and Harper, P and Thatcher, N (2000) A randomised phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. British Journal of Cancer , 82 (6) 1158 - 1162.

Middleton, MR and Ranson, M and Lee, SM and Bridgewater, J and McElhinney, RS and McMurry, TBH and Thatcher, N and Halbert, G and Armstrong, S and Margison, GP (2000) Phase I study of 4-bromothenylguanine (4-BTG, PaTrin 2), an alkyltransferase inactivator, and temozolomide. CLIN CANCER RES , 6 4574S - 4574S.

Mitjans, F and Meyer, T and Fittschen, C and Goodman, S and Jonczyk, A and Marshall, JF and Reyes, G and Piulats, J (2000) In vivo therapy of malignant melanoma by means of antagonists of alpha-v integrins. International Journal of Cancer , 87 (5) 716 - 723.

N

Napier, MP and Sharma, SK and Springer, CJ and Bagshawe, KD and Green, AJ and Martin, J and Stribbling, SM and Cushen, N and O'Malley, D and Begent, RH (2000) Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res , 6 (3) 765 - 772.

Napier, MP and Sharma, SK and Springer, CJ and Bagshawe, KD and Green, AJ and Martin, J and Stribbling, SM and Cushen, N and O'Malley, D and Begent, RHJ (2000) Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. CLIN CANCER RES , 6 (3) 765 - 772.

O

Osborne, M and Glynne-Jones, A and Makris, A (2000) Chemoradiation followed by immediate boost in squamous cell carcinoma of the anus. British Journal of Cancer , 83 71 - ?.

P

Patterson, LH and Paniwynk, Z and Pohrs, K and Teesdale-Spittle, PH and Hartley, JA and Plumb, J (2000) A novel alkylating anthraquinone that is effective against resistant ovarian cancer cells. Proceedings of the American Association for Cancer Research , 41 2701 - ?.

Pavlidis, N and Aamdal, S and Awada, A and Calvert, H and Fumoleau, P and Sorio, R and Punt, C and Verweij, J and van Oosterom, A and Morant, R and Wanders, J and Hanauske, AR (2000) Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). CANCER CHEMOTH PHARM , 46 (2) 167 - 171.

Pedley, RB and Sharma, SK and Boxer, G and Flynn, AA and Boden, R and Watson, R and Dearling, J and Hill, SA and Springer, CJ and Begent, RHJ (2000) Tumour eradication by combined antibody-directed and antivascular therapy. British Journal of Cancer , 83 19 - ?.

Pedley, RB and Sharma, SK and Boxer, GM and Flynn, AA and Boden, R and Watson, R and Dearling, J and Hill, SA and Springer, CJAB and R, HJ (2000) Tumour eradication by combined antibody-directed and antivascular therapy. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 13 - ?).

Pedley, RB and Sharma, SK and Hill, SA and Boden, R and Boxer, GM and Flynn, AA and Springer, CJAB and R, HJ (2000) Tumour ablation by combined antibody-directed and antivascular therapies. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 79 - ?).

Pettet, E and Phillips, H and Jackson, S and Saunders, MI (2000) The time span between symptom onset and the start of radiotherapy in the treatment of head and neck tumours - A retrospective review. British Journal of Cancer , 83 78 - ?.

Pigott, KH and Dische, S and Vojnovic, B and Saunders, MI (2000) Sweat gland function as a measure of radiation change. Radiotherapy And Oncology , 54 (1) 79 - 85.

Porrello, A and Cerone, MA and Coen, S and Gurtner, A and Fontemaggi, G and Cimino, L and Piaggio, G and Sacchi, A and Soddu, S (2000) p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol , 151 (6) 1295 - 1304.

Pritchard, JK and Lewis, I and Whelan, JS and Hale, J and Pagonis, C and Durrant, LG (2000) Immune response to the anti-idiotype cancer vaccine, 105AD7, following chemotherapy in osteosarcoma patients. In: SIOP, Amsterdam Oct 2000.

R

Raymond, EE and Fumoleau, P and Roche, H and Schellens, JHM and Dittrich, C and Punt, CJA and Droz, JP and Calvert, AH and van Oosterom, A and Wanders, J and Ravic, M (2000) Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070, a novel chloroindolyl-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clinical Cancer Research , 6 315 - ?.

Rogers, S and Whelan, JS (2000) Cerebral metastases from malignant fibrous histiocytoma of bone. Sarcoma , 4 125 - 128.
An open access publication

Roos, DE and Davis, SR and O'Brien, PC and Hoskin, PJ (2000) Eligibility audits form the randomised neuropathic bone trial (TROG 96.05). Australasian Radiology , 44 303 - 307.

Roos, DE and O'Brien, PC and Smith, JG and Spry, NA and Hoskin, PJ and Burmeister, BH and Turner, SL and Bernshaw, DM (2000) A role for radiotherapy in neuropathic bone pain: Preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05). International Journal of Radiation Oncology Biology Physics , 46 (4) 975 - 981.

Rudd, RM and Gower, NH and James, LE and Gregory, W and Eisen, TQ and Lee, SM and et, A (2000) A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). In: (Proceedings) 9th World Conference on Lung Cancer, Tokyo, Japan.. (pp. 21 - ?). Lung Cancer

S

Saifuddin, A and Whelan, J and Pringle, JAS and Cannon, SR (2000) Malignant round cell tumours of bone: atypical clinical and imaging features. SKELETAL RADIOL , 29 (11) 646 - 651.

Saunders, MI (2000) The implications and opportunities of the CHART trial in the treatment of non-small cell lung cancer. British Journal of Cancer , 83 S5 - ?.

Shah, N and Groom, N and Jackson, S and Sibtain, A and Hoskin, P (2000) A pilot study to assess the feasibility of prior scalp cooling with palliative whole brain radiotherapy. British Journal of Radiology , 73 (869) 514 - 516.

Shah, N and Hoskin, P and McMillan, A and Gibson, P and Lowe, J and Wong, WL (2000) The impact of FDG positron emission tomography imaging on the management of lymphomas. British Journal of Radiology , 73 (869) 482 - 487.

Shah, N and Hoskin, P and Sibtain, A and Baddeley, H and Taylor, J and Saunders, M (2000) Blood oxygen level dependent (BOLD) MRI imaging: A non invasive assessment of hypoxia and perfusion in solid tumours. British Journal of Cancer , 83 15 - ?.

Shah, N and Saunders, M and Dische, S (2000) A pilot study of postoperative CHART and CHARTWEL in head and neck cancer. British Journal of Cancer , 83 77 - ?.

Shah, N and Sibtain, A and Saunders, MI and Townsend, E and Wong, WL (2000) High FDG uptake in a schwanomma: A PET study. Journal Of Computer Assisted Tomography , 24 (1) 55 - 56.

Shamash, J and Lee, SM and Radford, JA and Rohatiner, AZS and Chang, J and Morgenstern, OR and Scarffe, JH and Deakin, DP and Lister, TA (2000) Patterns of relapse and subsequent management following high dose chemotherapy with autologous haemopoietic support in relapsed or refractory Hodgkin's lymphoma. Annals of Oncology , 11 (6) 715 - 719.

Sharma, SK and Pedley, RB and Bhatia, J and Minton, N and Chester, KA and Begent, RHJ (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: British Journal of Cancer. (pp. 172 - 172).

Sharma, SK and Pedley, RB and Bhatia, J and Minton, N and Chester, KA and Begent, RHJ (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. British Journal of Cancer , 83 172 - ?.

Sharma, SK and Pedley, RB and Bhatia, J and Minton, N and Chester, KA and Begent, RHJ (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. BRIT J CANCER , 83 71 - 71.

Sharma, SK and Pedley, RB and Bhatia, J and Minton, N and Chester, KA and Begent, RHJ (2000) In vivo characteristics of an engineered fusion protein for use in ADEPT. In: (Proceedings) British Journal of Cancer. (pp. 71 - 71).

Sharma, SK and Pedley, RB and Bhatia, J and Minton, N and Chester, KAAB and R, HJ (2000) In vivo characteristics of a glycosylated fusion protein for prodrug activation. In: (Proceedings) Proceedings American Association for Cancer Research. (pp. 710 - ?).

Short, S (2000) UNSPECIFIED In: (Proceedings) Radiobiology 2000, Trivandrum, India.

Short, S and C, B and M, (2000) The treatment of malignant cerebral tumours. Hospital Medicine , 61 (11) 772 - 777.

Short, SC and Traish, D and Dowe, A and Hines, F and Brada, M (2000) UNSPECIFIED In: (Proceedings) 4th Congress of the European Association for Neuro-Oncology.

Sibtain, A and Bradshaw, A and Shah, N and Hoskin, PJ (2000) Late complications of mantle radiotherapy for Hodgkin's lymphoma. British Journal of Cancer , 83 223 - ?.

Sibtain, A and Hill, SA and Goodchild, KA and Shah, N and Saunders, MI and Hoskin, PJ (2000) Modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. British Journal of Cancer , 83 15 - ?.

Sibtain, A and Shah, N and Saunders, MI and Hoskin, PJ (2000) Is there a relationship between pre-treatment haemoglobin and outcome in non-small cell lung cancer treated with radiotherapy? British Journal of Cancer , 83 58 - ?.

Smith, PG and Thomas, HD and Barlow, HC and Griffin, RJ and Golding, BT and Calvert, AH and Newell, DR and Curtin, NJ (2000) In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU3121. Clinical Cancer Research , 6 445 - ?.

Spanswick, VJ and Craddock, C and Sekhar, M and Hartley, JA (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 35 - ?.

Spanswick, VJ and Craddock, C and Sekhar, M and Hartley, JA (2000) Repair of DNA interstrand crosslinks as a mechanism clinical resistance to melphalan in multiple myeloma. BRIT J CANCER , 83 16 - 16.

Spanswick, VJ and Craddock, C and Sekhar, M and Hartley, JA (2000) Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. British Journal of Cancer , 83 (Suppl) 35 - ?.

Spencer, DIR and Purdy, D and Minton, N and Whitelegg, NR and Rees, AR and Begent, RHJ and Chester, KA (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. British Journal of Cancer , 83 (Suppl) 171 - ?.

Spencer, DIR and Purdy, D and Minton, N and Whitelegg, NR and Rees, AR and Begent, RHJ and Chester, KA (2000) Mutating ADEPT enzyme CPG2 to reduce its immunogenicity. BRIT J CANCER , 83 71 - 71.

Strauss, S and McTiernan, A and Driver, D and Hall-Craggs, M and Sandison, A and Cassoni, A and Kilby, A and Michelagnoli, M and Pringle, J and Cobb, J and Witt, J and Cannon, S and Briggs, T and Whelan, JS (2000) A single centre experience of an intensive induction therapy (VIDE) including stem cell collection for Ewing’s family of tumours (EFT). In: European Musculoskeletal Oncology Society Meeting, May 2000.

Strauss, S and McTiernan, A and Whelan, JS (2000) Spontaneous regression of pulmonary metastases in three patients with bone and soft tissue sarcomas. In: Musculoskeletal Oncology Society Meeting, May 2000.

T

ten Dam, GB and Zilch, CF and Wallace, D and Wieringa, B and Beverley, PCL and Poels, LG and Screaton, GR (2000) Regulation of alternative splicing of CD45 by antagonistic effects of SR protein splicing factors. J IMMUNOL , 164 (10) 5287 - 5295.

Thomas, HD and Lind, MJ and Ford, J and Bleehen, N and Calvert, AH and Boddy, AV (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours. CANCER CHEMOTH PHARM , 45 (4) 284 - 290.

Tolner, B and Hartley, JA and Hochhauser, D (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. British Journal of Cancer , 83 165 - ?.

Tolner, B and Hartley, JA and Hochhauser, D (2000) Modulation of topoisomerase II alpha expression at confluence by minor groove binders. BRIT J CANCER , 83 70 - 70.

Tsiompanou, E and Boxer, GM and Levine, T and Begent, RHJ (2000) Immunohistochemical expression of vascular endothelial growth factor (VEGF) and vessel counting as prognostic indicators in node-negative colorectal cancer. BRIT J CANCER , 83 29 - 29.

V

Verweij, J and Lee, SM and Ruka, W and Buesa, J and Coleman, R and van, HR and Seynaeve, C and di, PED and van, GM and Tonelli, D and Judson, IR (2000) Randomised phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. Journal of Clinical Oncology , 18 (10) 2081 - 2086.

W

Waibel, R and Stichelberger, R and Alberto, R and Schubiger, PA and Chester, KA and Begent, RHJ (2000) Site-directed labelling of single chain antibodies with 99(m)technetium and (188)rhenium. In: European Journal Of Nuclear Medicine. (pp. 15 - 15).

Westbury, C and Hines, F and Hawkes, E and Ashley, S and Brada, M (2000) Advice on hair and scalp care during cranial radiotherapy: a prospective randomized trial. Radiother Oncol , 54 (2) 109 - 116.

Westbury, C and Vini, L and Fisher, C and Harmer, C (2000) Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid , 10 (2) 171 - 176.

Whelan, JS (2000) Multidisciplinary care in a dedicated teenage cancer unit. In: Coping with Sarcoma, Berlin April 2000.

Whelan, JS and McTiernan, A (2000) A Phase II study of docetaxel for the treatment of recurrent osteosarcoma and Ewing’s tumours. In: European Musculoskeletal Oncology Society Meeting, May 2000.

Whelan, JS and Weeden, S and Uscinska, B and McTiernan, A (2000) Prolonged follow up of extremity osteosarcoma. Results from the European Osteosarcoma Intergroup. In: European Musculoskeletal Oncology Society Meeting, May 2000.

Whelan, JS and Weeden, S and Uscinska, B and McTiernan, A and European Osteosarcoma Intergrp, (2000) Long-term survival in localised extremity osteosarcoma: Mature follow-up from two randomised trials of the European Osteosarcoma Intergroup. In: BRIT J CANCER. (pp. 18 - 18). CHURCHILL LIVINGSTONE

Whelan, JS and Weeden, S and Uscinska, B and McTiernan, AFTEOI (2000) Localised extremity osteosarcoma: Mature survival data from two European Osteosarcoma Intergroup randomised clinical trials. In: New Orleans May 2000 Proc ASCO 2000;19: 552.

White, AW and Almassy, R and Calvert, AH and Curtin, NJ and Griffin, RJ and Hostomsky, Z and Maegley, K and Newell, DR and Srinivasan, S and Golding, BT (2000) Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J MED CHEM , 43 (22) 4084 - 4097. 10.1021/jm000950v.

This list was generated on Thu May 23 09:27:46 2013 BST.

Export as	RSS 2.0 RSS 1.0 Atom